Article
Liquid Biopsy Monitoring in BRAF V600E-Mutated Patients With Non-Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020).
JCO precision oncology - 1 Jun 2026
Leonetti Alessandro, Pluchino Monica, Minari Roberta, Passiglia Francesco, Pizzutilo Elio Gregory, Cortinovis Diego Luigi, Toschi Luca, Gelsomino Francesco, Frega Stefano, Metro Giulio, Belluomini Lorenzo, Montrone Michele, Camerini Andrea, Bertolini Alessandro, Baldini Editta, Mazzoni Francesca, Bria Emilio, Bertolini Federica, Del Conte Alessandro, Bordi Paola, Perrone Fabiana, Verzè Michela, D'Agnelli Simona, Onorini Paola, Cosenza Agnese, Facchinetti Francesco, Boni Luca, Tognetto Michele, Tiseo Marcello
Abstract excerpt
PURPOSE: Dabrafenib plus trametinib is a standard first-line treatment for BRAF V600E-mutated non-small cell lung cancer (NSCLC). The LiBRA study aimed to explore the role of liquid biopsy in detecting and monitoring BRAF V600E mutation, assessing its potential to predict treatment response and emerging resistance. MATERIALS AND METHODS: This prospective multicenter study enrolled patients with BRAF V600E-mutated...
Topics
Join the communities discussing this publication.